- Five-year SDAI remission rates were 30% in patients with chronic lung disease vs 44% in those without chronic lung disease.
- Patients with chronic lung disease had a 2.5-fold higher risk of serious adverse events during follow-up.
- Nonadherence to treat-to-target because of comorbidities or adverse events occurred in 34% of patients with chronic lung disease vs 19% without chronic lung disease.
- Interstitial lung disease worsened in 10 of 31 patients with baseline ILD, and three patients died following ILD exacerbation outside the formal observation period.
- The prospective study included 197 methotrexate-naïve patients with late-onset rheumatoid arthritis from a single Japanese center followed for 5 years.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Advertisement
Recommendations
Advertisement